Induction of immune tolerance with factor VIIi concentrate in patients with hemophilia a and inhibitors
Ewing, N.P.
Progress in Clinical and Biological Research 324: 59-68
1990
ISSN/ISBN: 0361-7742 PMID: 2106693 Document Number: 350378
Document emailed within 1 workday
Related Documents
DiMichele, D.; Kroner, B. 2000: The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis Haematologica 85(10 Suppl): 40Kessler, C.M.; Ludlam, C.A. 1993: The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group Seminars in Hematology 30(2 Suppl. 1): 22-27
Landolfi, R.; de Cristofaro, R.; Lazzareschi, I.; Riccardi, R.; Mariani, G. 2000: Immune tolerance by intermittent factor VIIi boluses in two high responder hemophilia a patients Haematologica 85(10 Suppl): 73-74
Scharf, R.; Kucharski, W.; Lopaciuk, S.; Celińska, W.; Dmytrow, A.; Domański, K.; Gonet, S.; Miastkowski, Z.; Nowakowska, I.; Przybylski, A. 1991: Preliminary experience with achieving immune tolerance in patients with hemophilia a and circulating factor VIIi inhibitor Acta Haematologica Polonica 22(1): 92-99
Kunst, V.A.; Nováková, I.R.; Haanen, C. 1989: Cryoprecipitate should have preference over factor VIII concentrate in the treatment of patients with hemophilia A Nederlands Tijdschrift Voor Geneeskunde 133(23): 1163-1166
Takahashi, I.; Furuta, M.; Mizuno, S.; Takamatsu, J.; Kamiya, T. 1993: Effect of substrate and diluent for factor VIIi activity in highly purified factor VIIi concentrate and patient plasma infused factor VIIi concentrate Rinsho Byori. Japanese Journal of Clinical Pathology 41(7): 825-830
Brakman, G.G. 1993: The occurrence of immunological tolerance to inhibitors of factors VIIi and IX in hemophilia patients Gematologiia i Transfuziologiia 38(2): 18-20
Allersma, D.P.; Smid, W.M.; van der Does, J.A.; van der Meer, J.; Briët, E. 1996: Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate Thrombosis and Haemostasis 75(2): 261-266
Scheibel, E.; Ingerslev, J.; Dalsgaard-Nielsen, J.; Stenbjerg, S.; Knudsen, J.B. 1987: Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: a description of eleven patients treated Thrombosis and Haemostasis 58(4): 1049-1052
Walker, I.; Poon, M.C. 1992: Recombinant factor VIII concentrate. The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic Directors Group Lancet 339(8784): 61-62
Iizuka, A.; Kuwashima, M.; Nagao, T. 1982: Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIIi or IX Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 45(5): 987-992
Lottenberg, R.; Kentro, T.B.; Kitchens, C.S. 1987: Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy Archives of Internal Medicine 147(6): 1077-1081
Teitel, J.M.; Lau, H.K.; Garvey, M.B. 2002: Discrepancies in measured factor VIIi activity in patients treated with factor VIIi concentrate of human or porcine origin Thrombosis and Haemostasis 88(1): 159-160
Brettler, D.B.; Forsberg, A.D.; Levine, P.H.; Aledort, L.M.; Hilgartner, M.W.; Kasper, C.K.; Lusher, J.M.; McMillan, C.; Roberts, H. 1989: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Archives of Internal Medicine 149(6): 1381-1385
Mahasandana, C.; Patharathienskul, D.; Suvatte, V. 1993: Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management Southeast Asian Journal of Tropical Medicine and Public Health 24(Suppl 1): 106-112
Davis, H.M.; Brown, S.K.; Nash, D.W.; Pennetti, A.M.; Salzman, P.M.; Schreiber, A.B.; Haimovich, J. 1990: Lack of immune response to mouse IgG in hemophilia a patients treated chronically with Monoclate, a monoclonal antibody affinity purified factor VIIi preparation Thrombosis and Haemostasis 63(3): 386-391
Ambriz-Fernández, R.; Reyna-Fregoso, M.P.; Pizzuto-Chávez, J.; Rodríguez-Moyado, H.; Farfán-Canto, J.M.; Trueba-Christy, E.; Collazo-Jaloma, J. 1985: Kinetics of the inhibitor of factor VIII:C in patients with hemophilia A. a study of the cooperative group of hemophilia Archivos de Investigacion Medica 16(3): 225-235
Hoyer, L.W.; Qian, J. 2000: Characterization of the immune response to factor VIIi using hemophilia A* mice Haematologica 85(10 Suppl): 100-102
Nemes, L.; Pitlik, E. 2000: New protocol for immune tolerance induction in acquired hemophilia Haematologica 85(10 Suppl): 64-68
Fijnvandraat, K.; Berntorp, E.; ten Cate, J.W.; Johnsson, H.; Peters, M.; Savidge, G.; Tengborn, L.; Spira, J.; Stahl, C. 1997: Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients Thrombosis and Haemostasis 77(2): 298-302